1
|
Oh Y, Stoll JR, Moskowitz A, Pulitzer M, Horwitz S, Myskowski P, Noor SJ. Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management. J Am Acad Dermatol 2021; 85:1093-1106. [PMID: 33945836 DOI: 10.1016/j.jaad.2021.04.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 04/14/2021] [Accepted: 04/16/2021] [Indexed: 10/21/2022]
Abstract
Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with clinicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy. Staging and treatment recommendations vary depending on the subtype, clinical behavior, and treatment response. Generally, for subtypes where staging is recommended, Ann Arbor or TNM staging specific to CTCL other than MF or SS are used. For many subtypes, there is no standard treatment to date. Available recommended treatments range widely from no active or minimal intervention with skin-directed therapy to aggressive systemic therapies including multiagent chemotherapy with consideration for hematopoietic stem cell transplant. Emerging targeted therapies, such as brentuximab, a chimeric antibody targeting CD30, show promise in altering the disease course of non-MF/SS CTCLs.
Collapse
Affiliation(s)
- Yuna Oh
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | | - Sarah J Noor
- Memorial Sloan Kettering Cancer Center, New York, NY.
| |
Collapse
|
2
|
Identification of Skin Lesions by Using Single-Step Multiframe Detector. J Clin Med 2021; 10:jcm10010144. [PMID: 33406761 PMCID: PMC7796252 DOI: 10.3390/jcm10010144] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 12/23/2020] [Accepted: 12/30/2020] [Indexed: 01/09/2023] Open
Abstract
An artificial intelligence algorithm to detect mycosis fungoides (MF), psoriasis (PSO), and atopic dermatitis (AD) is demonstrated. Results showed that 10 s was consumed by the single shot multibox detector (SSD) model to analyze 292 test images, among which 273 images were correctly detected. Verification of ground truth samples of this research come from pathological tissue slices and OCT analysis. The SSD diagnosis accuracy rate was 93%. The sensitivity values of the SSD model in diagnosing the skin lesions according to the symptoms of PSO, AD, MF, and normal were 96%, 80%, 94%, and 95%, and the corresponding precision were 96%, 86%, 98%, and 90%. The highest sensitivity rate was found in MF probably because of the spread of cancer cells in the skin and relatively large lesions of MF. Many differences were found in the accuracy between AD and the other diseases. The collected AD images were all in the elbow or arm and other joints, the area with AD was small, and the features were not obvious. Hence, the proposed SSD could be used to identify the four diseases by using skin image detection, but the diagnosis of AD was relatively poor.
Collapse
|
3
|
KANTARCIOĞLU COŞKUN S, ÖZTÜRK NAZLIOĞLU H, BÜYÜKUYSAL MÇ. Clinicopathological Features of Extranodal Lymphomas. KONURALP TIP DERGISI 2020. [DOI: 10.18521/ktd.789919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Erraji H, Hali F, Baline K, Marnissi F, Chiheb S. [Epidemiological and clinical profile and outcome in 166 mycosis fungoides patients in Casablanca]. Ann Dermatol Venereol 2019; 146:825-828. [PMID: 31519349 DOI: 10.1016/j.annder.2019.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Revised: 03/05/2019] [Accepted: 08/05/2019] [Indexed: 10/26/2022]
Affiliation(s)
- H Erraji
- Service de dermatologie, CHU Ibn Rochd, 20400 Casablanca, Maroc.
| | - F Hali
- Service de dermatologie, CHU Ibn Rochd, 20400 Casablanca, Maroc
| | - K Baline
- Service de dermatologie, CHU Ibn Rochd, 20400 Casablanca, Maroc
| | - F Marnissi
- Service d'anatomo-pathologie, CHU Ibn Rochd, 20400 Casablanca, Maroc
| | - S Chiheb
- Service de dermatologie, CHU Ibn Rochd, 20400 Casablanca, Maroc
| |
Collapse
|
5
|
Nudelmann LM, Bonamigo RR. Primary cutaneous lymphoma in southern Brazil: a 12-year single-center experience. Int J Dermatol 2015; 54:e512-20. [PMID: 26496535 DOI: 10.1111/ijd.12970] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 12/08/2014] [Accepted: 01/13/2015] [Indexed: 12/31/2022]
Abstract
BACKGROUND Primary cutaneous lymphomas (PCL) are a group of extranodal non-Hodgkin lymphomas presenting with no evidence of extracutaneous disease at the time of diagnosis. Few longitudinal studies of PCL have been conducted, particularly in South American populations. Our objective was to describe the behavior of PCL and evaluate patient survival in a cohort of patients from southern Brazil. METHODS We conducted a retrospective cohort study of all patients with a histopathological diagnosis of PCL receiving care at a tertiary referral center in southern Brazil from 2000 to 2012. Clinical, laboratory, and histopathological data, treatment variables, and survival curves were analyzed. RESULTS Eighty-nine patients with PCL were included, with a mean age at diagnosis of 58.9 years. Cutaneous T-cell and natural killer (NK) cell lymphomas (CTCL/NKCL) accounted for 78.4% of cases and cutaneous B-cell lymphomas (CBCL) for 21.6%; 57.4% of patients with CTCL/NKCL and 50% of patients with CBCL were male. Half of all cases were mycosis fungoides (MF). The 5-year survival rate was 74.8% for MF, 61% for Sézary syndrome, 87.5% for primary cutaneous CD30+ lymphoproliferative disorders, and 88.9% for primary cutaneous follicle center lymphoma. CONCLUSIONS In this cohort of patients with PCL from southern Brazil, CTCL/NKCL was more prevalent than CBCL, and the MF subtype was predominant. Survival curves were similar to those reported in the literature, except for Sézary syndrome, which had a better prognosis in this sample.
Collapse
Affiliation(s)
- Lisia M Nudelmann
- Department of Dermatology, Universidade Luterana do Brasil, Canoas, Brazil.,Department of Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil
| | - Renan R Bonamigo
- Department of Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.,Department of Dermatology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil
| |
Collapse
|
6
|
Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. Postepy Dermatol Alergol 2015; 32:67-72. [PMID: 26015774 PMCID: PMC4436229 DOI: 10.5114/pdia.2014.40941] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Revised: 09/20/2013] [Accepted: 10/28/2013] [Indexed: 01/22/2023] Open
Abstract
INTRODUCTION Treatment of T cell cutaneous lymphoma( CTCL) is a controversial subject and the effectiveness of treatment is still low. AIM Report of single center experience of management CTCL after progression after first line treatment. MATERIAL AND METHODS We present 41 patients with CTCL, 29 received interferon α2b in first line, and 12 of them received second line therapy. RESULTS Overall response rate for second line therapy was 60%. CONCLUSIONS Results of the follow-up of patients with mycosis fungoides after interferon α2b treatment failure with the literature review and discussion.
Collapse
|
7
|
Hunger RE, Sallam M, Yawalkar N. Photodynamic therapy for mycosis fungoides: a case series and review of the literature. VESTNIK DERMATOLOGII I VENEROLOGII 2015. [DOI: 10.25208/0042-4609-2015-91-1-24-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma. In early stages of the disease, topical therapeutic approaches like steroids, chemotherapy, phototherapy or spot radiation therapy are most commonly used. Photodynamic therapy (PDT) is widely executed in the treatment of actinic keratosis and superficial basal cell carcinoma. The effective use of PDT for early forms of MF has been previously demonstrated in a series of cases. In this instance, the treatment of MF (n = 6, 11 lesions) with methyl alanine PDT (MAL-PDT) in 73% of the treated lesions showed a complete response. Within the timeframe of 25-51 months, no recurrence of the successfully treated lesions was observed, on the contrary some of the patients developed new lesions on different sites. Hence, this case study shows that patients having a single or few MF lesions can be successfully treated by PDT.
Collapse
|
8
|
Affiliation(s)
- Jason B Kaplan
- Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, 645 N. Michigan Ave, Chicago, IL 60611, USA
| | | | | |
Collapse
|
9
|
Wu P, Huang V, Bigby M. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review. Br J Dermatol 2014; 170:1015-20. [DOI: 10.1111/bjd.12954] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2014] [Indexed: 12/01/2022]
Affiliation(s)
- P.A. Wu
- Department of Dermatology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Ave, GZ522 Boston MA 02215 U.S.A
| | - V. Huang
- Department of Dermatology; Brigham and Women's Hospital; Harvard Medical School; Boston MA U.S.A
| | - M.E. Bigby
- Department of Dermatology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Ave, GZ522 Boston MA 02215 U.S.A
| |
Collapse
|
10
|
Koh MJA, Chong WS. Narrow-band ultraviolet B phototherapy for mycosis fungoides in children. Clin Exp Dermatol 2014; 39:474-8. [DOI: 10.1111/ced.12364] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/19/2014] [Indexed: 11/27/2022]
Affiliation(s)
- M. J.-A. Koh
- Dermatology Service; KK Women's and Children's Hospital; Singapore
| | | |
Collapse
|
11
|
Day A, Abramson AK, Patel M, Warren RB, Menter MA. The spectrum of oculocutaneous disease. J Am Acad Dermatol 2014; 70:821.e1-19. [DOI: 10.1016/j.jaad.2013.12.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 12/18/2013] [Accepted: 12/29/2013] [Indexed: 11/27/2022]
|
12
|
Piccinno R, Caccialanza M, Çuka E, Recalcati S. Localized conventional radiotherapy in the treatment of Mycosis Fungoides: our experience in 100 patients. J Eur Acad Dermatol Venereol 2013; 28:1040-4. [PMID: 23998331 DOI: 10.1111/jdv.12254] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 07/25/2013] [Indexed: 12/26/2022]
Abstract
BACKGROUND Radiotherapy (RT) is one of the treatments of choice as skin-directed therapy in Mycosis Fungoides (MF), both in first stages of the disease as total skin electron beam irradiation and in tumoural stage as localized treatment with conventional energies or electrons. OBJECTIVE Through a retrospective study, to evaluate the results of localized superficial RT in a series of 100 patients affected by MF. METHODS All the patients, after diagnosis supported by histological and immunophenotyping investigations, have been treated with conventional RT (range 50-150 kV) and a total dose ranging from 9 to 40 Gy. RESULTS Complete remission of the irradiated lesion has been observed in 88%, partial remission in 6% and non-response in 2%. Four patients were lost to follow-up. Local relapse has been observed in 13 lesions, with a local control rate of 85% after 5 years from the end of RT. Cosmetic results have been good and acceptable in 93% of cases. The treatment has been always well tolerated. The results confirm to be dose dependent, and show that better response is found in the range of higher energies. CONCLUSION Localized RT is an effective and safe tool in the care and palliation of MF.
Collapse
Affiliation(s)
- R Piccinno
- Servizio di Fotoradioterapia, UO Dermatologia, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | | | | | | |
Collapse
|
13
|
Quaglino P, Knobler R, Fierro MT, Savoia P, Marra E, Fava P, Bernengo MG. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. Int J Dermatol 2013; 52:1308-18. [PMID: 23786842 DOI: 10.1111/ijd.12121] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Extracorporeal photopheresis (ECP) is a therapeutic procedure in which leukapheresed peripheral blood mononuclear cells are exposed to ultraviolet A in the presence of the photosensitizer 8-methoxypsoralen and then reinfused. Several guidelines recommend ECP as a treatment of choice in erythrodermic primary cutaneous T-cell lymphomas (E-CTCL). However, the level of evidence is low due to the rarity of this disease and the lack of randomized controlled trials. We performed a review of the English literature, restricting our analysis to studies including erythrodermic patients and more than 10 cases. Based on these criteria, we identified 28 studies, with a total of 407 patients. The median response rate in erythrodermic patients was 63% (range 31-86%), with a complete response rate ranging between 0 and 62% (median 20%). In our experience, we treated 51 patients with E-CTCL since 1992. A clinical response was obtained in 32 of 51 patients (63%), with a 16% complete response rate. The median time for response induction was eight months (range: 1-23). The median response duration was 22.4 months (range six months to 11 years). The treatment was generally well tolerated without systemic toxicities grade III-IV. The pretreatment parameters significantly associated with a higher likelihood to obtain a clinical response were the B-score in the peripheral blood, CD4/CD8 ratio, and amount of circulating CD3+CD8+ cells. Literature data together with our personal experience clearly support the clinical activity and tolerability of ECP in patients with E-CTCL. Prospective controlled clinical trials are strongly recommended to better document the evidence.
Collapse
Affiliation(s)
- Pietro Quaglino
- Department of Medical Sciences and Human Oncology, Section of Dermato-Oncology, University of Turin, Turin, Italy
| | | | | | | | | | | | | |
Collapse
|
14
|
Sarantopoulos GP, Palla B, Said J, Kinney MC, Swerdlow SM, Willemze R, Binder SW. Mimics of cutaneous lymphoma: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013; 139:536-51. [PMID: 23525620 DOI: 10.1309/ajcpx4bxtp2qbrko] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The Society for Hematopathology and European Association for Haematopathology workshop, from October 27 to 29, 2011, in Los Angeles, CA, exhibited many exemplary skin biopsy specimens with interesting inflammatory changes mimicking features of cutaneous lymphoma. This article reviews features observed in cutaneous lymphoid hyperplasia, cutaneous drug reactions, lupus-associated panniculitis, pityriasis lichenoides, hypereosinophilic syndrome, histiocytic necrotizing lymphadenitis, traumatic ulcerative granuloma with stromal eosinophils, and pigmented purpuric dermatosis, as well as a brief review of the pertinent literature and discussion of submitted conference cases. For the pathologist, it is important to be aware of diagnostic pitfalls as well as the limitations of ancillary testing (eg, clonality studies). Finally, correlation with total clinical information, good communication with clinical colleagues, close clinical follow-up with rebiopsy, and prudent use of laboratory studies are vital and will likely offer the best path toward a correct diagnosis.
Collapse
Affiliation(s)
| | - Beth Palla
- Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, CA
| | - Jonathan Said
- Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, CA
| | | | - Steven M. Swerdlow
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Rein Willemze
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands
| | - Scott W. Binder
- Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, CA
| |
Collapse
|
15
|
Döbbeling U, Waeckerle-Men Y, Zabel F, Graf N, Kündig TM, Johansen P. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Exp Dermatol 2013; 22:119-24. [DOI: 10.1111/exd.12086] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2013] [Indexed: 12/19/2022]
Affiliation(s)
- Udo Döbbeling
- Department of Dermatology; University Hospital Zurich; Zurich; Switzerland
| | - Ying Waeckerle-Men
- Department of Dermatology; University Hospital Zurich; Zurich; Switzerland
| | - Franziska Zabel
- Department of Dermatology; University Hospital Zurich; Zurich; Switzerland
| | - Nicole Graf
- Center for Clinical Research; University of Zurich; Zurich; Switzerland
| | - Thomas M. Kündig
- Department of Dermatology; University Hospital Zurich; Zurich; Switzerland
| | - Pål Johansen
- Department of Dermatology; University Hospital Zurich; Zurich; Switzerland
| |
Collapse
|
16
|
Kim M, Thompson LA, Wenger SD, O'Bryant CL. Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma. Ann Pharmacother 2012; 46:1340-8. [DOI: 10.1345/aph.1r036] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Objective: To evaluate the efficacy and safety of romidepsin in refractory cutaneous T-cell lymphoma (CTCL). Data Sources: An English-language literature search of PubMed and MEDLINE (Nov 2011–April 2012) was performed using the terms romidepsin, CTCL, and depsipeptide (FK228). The National Comprehensive Cancer Network guidelines, American Society of Clinical Oncology abstracts, American Society of Hematology abstracts, clinical trial registry, and prescribing information from the manufacturer were reviewed for additional information. Study Selection and Data Extraction: Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. All peer-reviewed articles with clinically relevant information were evaluated for inclusion. Data Synthesis: In advanced stage CTCL, single or combination chemotherapy regimen responses are variable and lack durability. Romidepsin is a histone deacetylase inhibitor approved for refractory cutaneous T-cell lymphoma, Romidepsin has shown an improvement in duration of response and pruritus over traditional therapy. In 2 independent Phase 2 trials, romidepsin showed an overall response rate of 34% and durable response of 13–15 months in patients with refractory CTCL. The most frequent toxicities of romidepsin include nausea. vomiting, fatigue, or myelosuppresston. Clinically insignificant QT interval changes have been observed but did not correlate with a decrease in left ventricular ejection fraction, or elevated laboratory markers of myocardial damage. Conclusions: Romidepsin is an effective, durable, and well-tolerated single-agent therapy in patients with refractory CTCL and should be considered for formulary addition in this population.
Collapse
Affiliation(s)
- Miryoung Kim
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora
| | - Lisa A Thompson
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado
| | - Sarah D Wenger
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado
| | - Cindy L O'Bryant
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado
| |
Collapse
|
17
|
Sia WT, Tan PL, Chuah KL, Teoh LC. An unusual case of primary cutaneous lymphoma presenting in the upper extremity: a case report. ACTA ACUST UNITED AC 2012; 17:259-61. [PMID: 22745096 DOI: 10.1142/s021881041272029x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 10/31/2011] [Accepted: 11/09/2011] [Indexed: 11/18/2022]
Abstract
Primary cutaneous lymphomas rarely present to the hand surgeon. Diagnosis of primary cutaneous lymphoma in the upper extremity can be difficult to make, as they are rare, and may be mistaken for other lesions. We report an unusual case of primary cutaneous lymphoma presenting in the upper extremity. This rare differential should be considered when encountered with a lump of similar appearance in the upper extremity.
Collapse
|
18
|
Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2011; 53:789-95. [DOI: 10.3109/10428194.2011.629701] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
19
|
JANG MS, BAEK JW, KANG DY, KANG JS, SUH KS, KIM ST. Subcutaneous panniculitis-like T-cell lymphoma: Successful treatment with systemic steroid alone. J Dermatol 2011; 39:96-9. [DOI: 10.1111/j.1346-8138.2011.01291.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Chen R, Liu L, Liang YM. Treatment relapsed subcutaneous panniculitis-like T-cell lymphoma together HPS by Cyclosporin A. Hematol Rep 2010; 2:e9. [PMID: 22184522 PMCID: PMC3222267 DOI: 10.4081/hr.2010.e9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2010] [Accepted: 11/23/2010] [Indexed: 11/23/2022] Open
Abstract
A 25-year-old man was diagnosised subcutaneous panniculitis-like T-cell lymphoma (SPTCL) through biopsy of a nodule from the anterior chest. After the treatment with prednisone 90 mg 3 weeks and tapered off in 1 month, the disease released, but relapsed together with symptions of hemophagocytic syndrome eight months after the termination of prednisone. CHOEP recipe was given but with unsatisfactory result until cyclosporine was prescribed. Cyclosporine was removed 6 months later. There is no evidence of clinical relapse 1 year later. This case suggest that cyclosporine could be a selectable treatment even in relapsed SPTCL.
Collapse
Affiliation(s)
- Ren'an Chen
- Department of Haematology, Tang du Hospital, Fourth Military Medical University, Xi'an, China
| | | | | |
Collapse
|